The strong Q4 beat and above-consensus FY27 guidance (6.75-7.25% organic growth, $5.90-$6.00 EPS) should drive positive momentum. Watch for margin recovery as tariff and Blackstone headwinds ease. The 49th consecutive dividend increase reinforces capital return commitment.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $78.03entry
- T+1 · 6mo ago +4.97%α +4.57% · $81.91
- T+5 · 5mo ago +2.85%α +6.67% · $80.25
- T+20 · 5mo ago +1.50%α +2.63% · $79.20
- T+60 · 3mo ago +15.30%α +13.07% · $89.97
Price Chart
How similar events traded
Executive Summary
Medtronic reported Q4 FY26 revenue of $9.807B (+9.9% YoY, +6.6% organic), beating the $9.61B consensus, and non-GAAP diluted EPS of $1.55, in line with the $1.55 consensus. The company guided FY27 organic revenue growth of 6.75%-7.25% and non-GAAP EPS of $5.90-$6.00, representing 6.7%-8.5% growth. Strong top-line performance and raised guidance are positive, but non-GAAP operating margin contracted 230bps YoY in Q4 and 130bps for FY26, with headwinds from tariffs and the MiniMed Blackstone payment.
Key Financial Metrics
Key Facts
- Q4 FY26 revenue $9.807B, +9.9% reported, +6.6% organic, 90bps ahead of implied guidance
- Q4 GAAP diluted EPS $0.96 (+17.1% YoY); non-GAAP diluted EPS $1.55 (-4.3% YoY)
- FY26 revenue $36.364B (+8.4% reported, +5.8% organic); FY26 non-GAAP EPS $5.53 (+0.7% YoY)
- FY27 guidance: organic revenue growth 6.75%-7.25%; non-GAAP EPS $5.90-$6.00 (6.7%-8.5% growth)
- Dividend increased to $0.72/quarter ($2.88 annual), 49th consecutive annual increase
- Cardiac Ablation Solutions revenue +78% globally, +124% US; Cardiovascular portfolio +10.1% organic
- Q4 non-GAAP operating margin 25.5%, down 230bps YoY, impacted by 160bps from MiniMed Blackstone payment and 80bps from tariffs
- FY26 free cash flow $5.426B, +4.6% YoY; returned $4.2B to shareholders
Financial Impact
Q4 revenue beat consensus by ~$197M (2.0%); FY27 EPS guidance midpoint $5.95 implies ~7.6% growth vs FY26 non-GAAP $5.53
Risk Factors
- Non-GAAP operating margin contraction of 130bps in FY26 and 230bps in Q4 raises profitability concerns
- Tariff headwinds of ~50bps on FY26 margins and potential escalation in FY27
- Diabetes business separation structure remains undecided, creating execution uncertainty
- FY26 non-GAAP EPS growth was only +0.7% despite 5.8% organic revenue growth, indicating cost pressures
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-040034 |
| Document: mdt-20260603.htm | 0001628280-26-040034 |
| Document: 0001628280-26-040034-index-headers.html | 0001628280-26-040034 |
| Document: 0001628280-26-040034-index.html | 0001628280-26-040034 |
| Document: 0001628280-26-040034.txt | 0001628280-26-040034 |
| 8-K Data (Synthetic) | 0001628280-26-040034 |
Track record
53 reports on MDT
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +15.29% at T+60 after the May 19, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $101.59 Now $102.88 +1.27% settles Feb 8
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $98.88 Now $102.88 +4.05% settles Feb 1
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $94.63 Now $102.88 +8.72% settles Jan 15
- Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
- Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
- Oct 15, 20264w ago 144 Neutral 3/10 Entry $95.45 Now $102.88 +7.78% settles Jan 12
- Oct 14, 20264w ago SC TO-I/A Neutral 5/10 Entry $94.23 Now $102.88 +9.18% settles Jan 11
- Oct 14, 20264w ago 425 Neutral 5/10 Entry $94.23 Now $102.88 +9.18% settles Jan 11
- Oct 13, 20264w ago SC TO-I/A Neutral 5/10 Entry $93.01 Now $102.88 +10.61% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers